Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A sterile **intravenous crystalloid and dextrose combination solution** containing sodium lactate, calcium chloride, sodium chloride, potassium chloride, and dextrose monohydrate, used as a parenteral source of water, electrolytes, and calories and as an **alkalinizing agent**. The product is marketed as Lactated Ringer's and Dextrose Injection, including 5% dextrose formulations, and is manufactured by ICU Medical and marketed under labeling historically associated with Hospira and Pfizer. Its pharmacologic activity derives from replacement of extracellular fluid and electrolytes, provision of glucose calories via dextrose, and buffering of metabolic acidosis through hepatic conversion of lactate to bicarbonate; it does not have a single discrete molecular target and instead acts through restoration of **fluid balance, electrolyte homeostasis, acid-base balance, and caloric support** in adults and pediatric patients requiring intravenous replacement therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium lactate + calcium chloride + sodium chloride + potassium chloride + dextrose monohydrate.